Table 1.
Characteristics of included studies.
| Study(Trs) | Age • T • C |
Sample Size (male/female) • T • C |
Course of the Disease • T • C |
Intervention • T • C |
Acupoints | EA parameters,Treatment Frequency and Duration • T • C |
Outcomes • Major • Minor |
Adverse events • T • C |
|---|---|---|---|---|---|---|---|---|
| Liu L 2023 | • 56 ± 12Y • 55 ± 12Y |
• 30(30/0) • 29(29/0) |
• 11.0 ± 6.7H • 10.7 ± 6.6H |
• Electroacupuncture +Diclofenac sodium • Diclofenac sodium |
Sanyinjiao(SP6) Dadu(SP2),Taichong (LR3), Taibai(SP3), Neiting(ST44),Zusanli (ST36),Yinlingquan(SP9) |
• 2Hz, Tolerated by the patient, 30 min, once • Oral medication: Diclofenac sodium, 50mg, once |
• VAS • Joint Pain and Swelling Score |
• None • 2 Diminished appetite |
| Wu B 2021 | • 51.3 ± 5.6Y • 52.7 ± 6.1Y |
• 43(30/13) • 43(31/12) |
• 18.65 ± 6.48H • 20.36 ± 7.52H |
• Electroacupuncture +Loxoprofen Sodium • Loxoprofen Sodium |
Sanyinjiao(SP6), Taichong(LR3),Zusanli (ST36),Yinlingquan(SP9) |
• 2Hz, 1mA, 30 min×1Week • Oral medication: Loxoprofen Sodiumn, 60mg, TID×1Week |
• Effective rate, VAS • CRP, IL-1β |
• 3 Dausea and fatigue • 4 Dausea and fatigue |
| Zhong Y 2020 | • 41 ± 8Y • 41 ± 8 Y |
• 41(31/10) • 41(33/8) |
• 4.25 ± 0.58D • 4.31 ± 0.61D |
• Electroacupuncture +Colchicine; Allopurinol; • Colchicine; Allopurinol |
Sanyinjiao(SP6), Taichong(LR3),Taibai(SP3), Zusanli(ST36),Hegu(LI4), Xingjian(LR2),Pishu(BL20), Yinlingquan(SP9) |
• 2/10/100 Hz,1 mA, 20min, QD× 2Weeks • Oral medication: Colchicine, first dose 1mg, then 0.5mg, BID; Allopurinol, 100mg,TID× 2Weeks |
• Effectiverate, VAS, SUA • ESR, Scr,IL-1β, TNF-α, COX-2 |
NR |
| Lan S 2018 | • 47.4 ± 8.3Y • 45.1 ± 9.2Y |
• 25(20/5) • 25(21/4) |
• 24.2 ± 10.2H • 25.5 ± 9.9H |
• Electroacupuncture + Etoricoxib • Etoricoxib |
Sanyinjiao(SP6), Zusanli(ST36),Yinlingquan (SP9), Fenglong(ST40), Quchi (LI11), Neiting(ST44Gongsun (SP4),Taixi(KI3) |
• 2/100HZ, 2-4mA,Tolerated by the patient, 30min,QD×1Week • Ora medication:Etoricoxib, 120mg, QD×1Week |
• Effective rate, VAS, SUA • ESR |
• 1 Light-headedness • 1 Light-headedness, 1 Mild nausea, |
| Wu Y 2012 | • 45.9 ± 3.9Y • 47.8 ± 4.7Y |
• 34(30/4) • 32(29/3) |
• 2.97 ± 1.61D • 3.12 ± 1.70D |
• Electroacupuncture + Fire acupuncture; Hemorrhage therapy; • Colchicine; Allopurinol |
Sanyinjiao(SP6), Zusanli(ST36),Ashipoint |
• 2Hz, 30min,QD×6Days • Oral medication:Colchicine, first dose 1mg, the 0.5mg;Allopurinol, 100mg, QD×6Days |
• Effective rate, VAS, SUA • ESR, CRP |
NR |
| Jin Z 2012 | • 38-60Y • 40-65Y |
• 30(27/3) • 30(29/1) |
• 1-10D • 2-12D |
• Electroacupuncture + Fire acupuncture; Hemorrhage therapy; • Colchicine; Indomethacin |
Sanyinjiao(SP6), Yinlingquan(SP9),Yanglingq- uan (GB34),Taibai(SP3),Taic- hong(LR3),Fenglong(ST40), Quchi (LI11),Hegu(LI4) |
• Current as tolerated by the patient, 40min, QD×2Weeks • Oral medication:Colchicine first dose 1mg, then 0.5mg,TID; Indomethacin, 25mg, TID×2Weeks |
• Effective rate, VAS • None |
NR |
| Liu Z 2010 | • 31-67Y • 30-65Y |
• 32(25/7) • 33(27/6) |
• 1-8W • 1-9W |
• Electroacupuncture + Angelica sinensis injection; • Colchicine; Indomethacin |
Sanyinjiao(SP6), Zusanli(ST36),Yinlingquan (SP9), Neiting(ST44),Taichong (LR3), Quchi(LI11),Hegu(LI4) |
• Current as tolerated by the patient, 30min,QD×2Weeks • Oral medication: Colchicine first dose 1mg, then 0.5mg,TID; Indomethacin 25mg, TID×2Weeks |
• Effective rate, VAS, SUA • None |
• None • 9 Gastrointestinal re actions; 3 Nervous system reaction; 1 Leucopenia; 2 Rash |
| Din Y 2009 | • 31-68Y • (30,70) |
• 35(25/10) • 35(26/9) |
• 5-11D • 5-12D |
• Electroacupuncture + Indomethacin; Allopurinol; • Indomethacin; Allopurinol |
Sanyinjiao(SP6), Zusanli(ST36),Ashi point |
• 0.5-2mA, 30min,QD×6Days • Oral medication: Indomethacin 25mg, TID;Allopurinol, 100mg, TID×6Days |
• Effective rate, VAS, SUA • None |
NR |
| Jin H 2009 | • 28-67Y • 30-65Y |
• 34(29/5) • 33(30/3) |
• 3-12D • 4-15D |
• Electroacupuncture + Hemorrhage therapy; • Indomethacin; Allopurinol |
Sanyinjiao(SP6), Yinlingquan(SP9),Ashi point |
• 2/100Hz, Current as tolerated by the patient, 30min,QD×1Week • Oral medication:Indomethacin, 25mg, TID;Allopurinol, 100mg, TID×1Week |
• Effective rate, VAS, SUA • None |
NR |
| He Y 2008 | • 28-67Y • 30-65Y |
• 30(27/3) • 30(28/2) |
• 2-13D • 3-12D |
• Electroacupuncture + Trimethoprim Injection; Lidocaine injection; • Colchicine;Indomethacin |
Sanyinjiao(SP6), Zusanli(ST36),Taixi(KI3),Gong- sun(SP4),Ashi point |
• Current as tolerated by the patient, 20min, QD×10Days • Oral medication: Colchicine first dose 1mg, then 0.5mg,TID; Indomethacin, 25mg, TID×10Days |
• Effective rate, • None |
• None • 8 Gastrointestinal re-actions; 3 Nervous system reaction; 1 Leucopenia; 1 Rash |
| Liu B 2008 | • 55.8 ± 8.9Y • 54.3 ± 8.4Y |
• 56(51/5) • 44(40/4) |
• 8.42 ± 1.91D • 8.11 ± 1.24D |
• Electroacupuncture + Lidocaine injection; Prednisolone Acetate Injection; • Indomethacin; Allopurinol |
Sanyinjiao(SP6), Yinbai(SP1),Zusanli(ST36),Yi- nlingquan(SP9),Yanglingquan (GB34),Fenglong(ST40), Taich- ong(LR3) |
• Current as tolerated by the patient, 30min, QD×1Week • Oral medication:Indomethacin, 25mg, TID×1Week Allopurinol, 100mg,TID×1Week |
• Effective rate, SUA • None |
NR |
| Zou R 2007 | • 32-70Y • 31-72Y |
• 30(24/6) • 30(25/5) |
• 4-12D • 5-13D |
• Electroacupuncture + Angelica sinensis injection; • Indomethacin; Allopurinol |
Sanyinjiao(SP6), Zusanli(ST36), Ashi point |
• 2/100Hz, 0.5-1mA, 30min, QD× 6Days • Oral medication:Indomethacin, 25mg, TID;Allopurinol, 100mg, TID×6Days |
• Effective rate, VAS, SUA • None |
NR |
| Zou R 2006 | • 31-70Y • 35-71Y |
• 30(26/4) • 30(28/2) |
• 5-13D • 3-10D |
• Electroacupuncture; • Indomethacin; Allopurinol |
Sanyinjiao(SP6), Zusanli(ST36), Ashi point |
• 2Hz, 0.5-2mA, 30min,QD×6Days • Oral medication:Indomethacin, 25mg, TID; Allopurinol, 100mg, TID× 6Days |
• Effective rate, VAS, SUA • UUA |
NR |
| Yin Y 2005 | • 60.3 ± 8.1Y • 62.5 ± 7.4Y |
• 40(28/12) • 30(19/11) |
• 6.9 ± 4.1D • 6.5 ± 3.3D |
• Electroacupuncture + Indomethacin; Benzbromarone; • Indomethacin; Benzbromarone |
Zusanli(ST36), Fenglong(ST40),Ashi point |
• Current as tolerated by the patient, 30min, QD×6Days • Oralmedication: Indomethacin, 25mg, TID;Benzbromarone, 50mg, QD×6Days |
• Effective rate, SUA • None |
NR |
| Zhang J 2005 | • 20-68Y • 21-67Y |
• 76(71/5) • 45(43/2) |
• 1-7D • 1-5D |
• Electroacupuncture + Compound Dansheninjection • Allopurinol |
Sanyinjiao(SP6), Yinbai(SP1),Dadun(LR1),Taich- ong (LR3),Yanglingquan(GB34), Yinlingquan(SP9) |
• Current as tolerated by the patient, 30min, QD×10Days • Oral medication:Allopurinol, 200mg, TID×10Days |
• Effective rate • None |
NR |
H,hours D,days; Y,years; W,weeks; T,treatment; C,control; NR,not recorded; QD,once a day; TID,thrice a day; VAS,visual rating scale; SUA= serum uric acid; CRP,C-reactive protein; IL,Interleukin; ESR,erythrocyte sedimentation rate; SCr,serum creatinine; UUA,urine uric acid.